AIM Stock Summary and Trading Ideas (Aim Immunotech | AMEX:AIM)

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Aim Immunotech trades on the AMEX stock market under the symbol AIM.

As of November 8, 2024, AIM stock price was flat at $0.24 with 206,504 million shares trading.

AIM has a beta of 1.59, meaning it tends to be more sensitive to market movements. AIM has a correlation of 0.06 to the broad based SPY ETF.

AIM has a market cap of $15.45 million. This is considered a Sub-Micro Cap stock.

Last quarter Aim Immunotech reported $50,000 in Revenue and -$.03 earnings per share. This beat revenue expectation by $40,000 and exceeded earnings estimates by $.09.

In the last 3 years, AIM traded as high as $1.79 and as low as $.21.

The top ETF exchange traded funds that AIM belongs to (by Net Assets): VTI, VXF.

AIM has underperformed the market in the last year with a price return of -46.4% while the SPY ETF gained +38.5%. AIM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.7% and -6.3%, respectively, while the SPY returned +15.7% and +3.3%, respectively.

AIM support price is $.23 and resistance is $.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AIM shares will trade within this expected range on the day.